Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06635148 · ClinicalTrials.gov registry record · Phase 2
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
A Phase 2 study of Geographic Atrophy and Macular Degeneration, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 274
- Enrollment target
- 20
- Study locations
NCT06635148: Recruiting Phase 2 study of Geographic Atrophy and Macular Degeneration, sponsored by Janssen Research & Development.
NCT06635148 is a Phase 2 study of Geographic Atrophy and Macular Degeneration that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 274 participants, above the 212-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (29% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06635148, a Phase 2 study of Geographic Atrophy and Macular Degeneration, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 274 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.
Primary Outcome
Number of participants with ocular and systemic TEAEs will be reported. An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as any adverse event occurring at or after the administration of study intervention.
Conditions Studied
Interventions
- DRUG JNJ-81201887
- OTHER Sham Procedure
Study Locations (20)
California
- Retina Consultants of Orange County - Fullerton
- Shiley Eye Institute Jacobs Retina Center - La Jolla
- California Retina Consultants - Oxnard
- California Eye Medical Specialists - Pasadena
- Retina Consultants San Diego - Poway
- Bay Area Retina Associates - Walnut Creek
Florida
- Retina Group of Florida - Fort Lauderdale
- VitreoRetinal Associates, PA - Gainesville
- Retina Specialty Institute - Pensacola
- Retina Vitreous Associates of Florida - St. Petersburg
Maryland
- Retina Specialists - Baltimore
- The Retina Group of Washington - Chevy Chase
- Cumberland Valley Retina Consultants - Hagerstown
Georgia
- Georgia Retina - Marietta
- Marietta Eye Clinic - Marietta
Arizona
- Retina Associates Southwest PC - Tucson
Illinois
- University Retina - Lemont
Indiana
- Midwest Eye Institute - Carmel
Maine
- Maine Eye Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2024-09-19 |
| Est. Completion | 2030-07-16 |
| Phase | Phase 2 |
What NCT06635148 shows while recruiting
NCT06635148 is an interventional study that assigns participants to a tested intervention. The registered 274 participants enrollment target is mid-sized for trials with a published cap, above the 212-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (29% higher).
The record links to 2 conditions, with Geographic Atrophy appearing as the primary indexed condition, and to 2 interventions - of which JNJ-81201887 is the first listed.
NCT06635148 names 20 study sites across 9 states, led by California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT06635148 about?
NCT06635148 is a clinical study titled "A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)". The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.
What is the current status of trial NCT06635148?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 274 participants. The study started on 2024-09-19. Estimated completion is 2030-07-16.
What conditions does trial NCT06635148 study?
This clinical trial studies the following conditions: Geographic Atrophy, Macular Degeneration.
What interventions are being tested in trial NCT06635148?
The interventions under investigation include: JNJ-81201887 (DRUG), Sham Procedure (OTHER).
Who is sponsoring clinical trial NCT06635148?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06635148 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06635148's enrollment target sits among peer trials
274 7th of 27 higher than 21 of 27 other Geographic Atrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Geographic Atrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
RECRUITING · Phase 2
-
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
RECRUITING · Phase 2
-
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03808922 · 274 participants · Phase 3
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- NCT04573504 · 274 participants · Phase 4
Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair
- NCT05289557 · 274 participants · Phase 3
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
- NCT05952583 · 274 participants
Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI